Showing 5721-5730 of 9078 results for "".
- Global Derm Market Reaches $11.6 Billionhttps://practicaldermatology.com/news/20120224-global_derm_market_reaches_116_billion/2459867/The global prescription dermatologic therapy market grew 6.2% from 2009 to 2001, to reach $11.6 billion. A new MarketWatch.com. report notes that the most dramatic gains were in the antiaging/photodamage, hair loss and hair removal, psoriasi
- Health Canada Approves BMS' Yervoy for Melanomahttps://practicaldermatology.com/news/20120208-health_canada_approves_bms_yervoy_for_melanoma/2459869/Health Canada approved Yervoy (ipilimumab 3mg/kg, Bristol-Myers Squibb) for the treatment of unresectable or metastatic melanoma in patients who have failed or do not tolerate other systemic therapy for advanced diseas
- Topical NAC Plus Doxycycline Shows Benefit in Moderate Acnehttps://practicaldermatology.com/news/topical-nac-plus-doxycycline-shows-benefit-in-moderate-acne/2486948/Topical N-acetylcysteine (NAC) plus doxycycline was associated with greater improvement than benzoyl peroxide (BPO) plus doxycycline in patients
- Study: No Meaningful Link Between AD and Adolescent Academic Performancehttps://practicaldermatology.com/news/study-no-meaningful-link-between-ad-and-adolescent-academic-performance/2486567/Atopic dermatitis (AD) was not found to impair academic performance in adolscent patients, according to results from a new analysis of two large European cohorts. Researchers looked at two large, population-based cohort studi
- IMMpactful: Risankizumab Outperforms Deucravacitinib in Moderate Psoriasis at 16 Weekshttps://practicaldermatology.com/news/immpactful-risankizumab-outperforms-deucravacitinib-in-moderate-psoriasis-at-16-weeks/2486443/Risankizumab achieved higher rates of PASI 90 and PASI 100 compared with deucravacitinib at 16 weeks, alongside greater improvements in patient-reported symptoms and quality of life, new results from the IMMpactful trial suggested.
- What New Secukinumab Data Mean for HS Patients: A Q&A with Dr. April Armstronghttps://practicaldermatology.com/news/what-new-secukinumab-data-mean-for-hs-patients-a-qa-with-dr-april-armstrong/2486412/In the following Q&A, Dr. April Armstrong, professor and chief of dermatology at UCLA and a study coauthor, talks with Practical Dermatology about the importance of new secukinumab data for patients with hidradenitis suppurativa (HS). Speaking on UCB's recently announced top
- Sclerotic cGVHD Patients Show Higher Risk for Outcome Reporting Mismatchhttps://practicaldermatology.com/news/patient-reported-cgvhd-worsening-linked-to-mortality-in-sclerotic-disease/2485447/A new longitudinal cohort study published in JAMA Dermatology showed differences in frequency and importance of discordance between clinician-reported and patient-reported outcomes in cutaneous chronic graft-vs-host disease (cG
- MEK Inhibition Shows Promise in Aggressive EB-Linked Skin Cancershttps://practicaldermatology.com/news/mek-inhibition-shows-promise-in-aggressive-eb-linked-skin-cancers/2485197/A transcriptome-driven drug repurposing strategy has identified selumetinib as a potential therapeutic candidate for aggressive squamous cell carcinomas (SCCs) arising in recessive dystrophic epidermolysis bullosa (RDEB). Resea
- Most Insurers Cover Botulinum Toxin for Axillary Hyperhidrosis: Analysishttps://practicaldermatology.com/news/most-insurers-cover-botulinum-toxin-for-axillary-hyperhidrosis-analysis/2484933/A new cross-sectional study published in the Journal of Drugs in Dermatology finds that while botulinum toxin is broadly covered by private insurers for the treatment of primary axillary hyperhidrosis, access barriers due to
- Smoking, PROs, and Attrition May Skew HS Study Outcomes: Commentaryhttps://practicaldermatology.com/news/smoking-pros-and-attrition-may-skew-hs-study-outcomes/2484927/A letter to the editor published in JAAD provided commentary and presented additional opportunities for further research on adalimumab and the effects of smoking on patient response while treating hidradenitis suppurativa (HS).